These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18411419)

  • 1. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
    Khouri IF; McLaughlin P; Saliba RM; Hosing C; Korbling M; Lee MS; Medeiros LJ; Fayad L; Samaniego F; Alousi A; Anderlini P; Couriel D; de Lima M; Giralt S; Neelapu SS; Ueno NT; Samuels BI; Hagemeister F; Kwak LW; Champlin RE
    Blood; 2008 Jun; 111(12):5530-6. PubMed ID: 18411419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
    Khouri IF; Saliba RM; Giralt SA; Lee MS; Okoroji GJ; Hagemeister FB; Korbling M; Younes A; Ippoliti C; Gajewski JL; McLaughlin P; Anderlini P; Donato ML; Cabanillas FF; Champlin RE
    Blood; 2001 Dec; 98(13):3595-9. PubMed ID: 11739162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation in follicular lymphoma.
    Khouri IF
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
    Sauter CS; Barker JN; Lechner L; Zheng J; Devlin SM; Papadopoulos EB; Perales MA; Jakubowski AA; Goldberg JD; Koehne G; Ceberio I; Giralt S; Zelenetz AD; Moskowitz CH; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):354-60. PubMed ID: 24315843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
    Tam CS; Khouri I
    Curr Hematol Malig Rep; 2007 Oct; 2(4):225-31. PubMed ID: 20425374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; Mackinnon S
    Blood; 2000 Oct; 96(7):2419-25. PubMed ID: 11001893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
    Corradini P; Tarella C; Olivieri A; Gianni AM; Voena C; Zallio F; Ladetto M; Falda M; Lucesole M; Dodero A; Ciceri F; Benedetti F; Rambaldi A; Sajeva MR; Tresoldi M; Pileri A; Bordignon C; Bregni M
    Blood; 2002 Jan; 99(1):75-82. PubMed ID: 11756155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
    Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Couriel D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE
    Haematologica; 2008 Feb; 93(2):257-64. PubMed ID: 18223284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.